Travere Therapeutics, Inc. (TVTX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-07

Key Insights

The reporting person, Roy D. Baynes, exercised 10,000 stock options at $26.52 and subsequently sold 10,000 shares at $33, indicating insider selling activity.
The sale was made pursuant to a pre-arranged 10b5-1 trading plan, suggesting the transaction was part of a planned strategy rather than opportunistic trading.
The reporting person still holds 37,500 shares of Travere Therapeutics, Inc. (TVTX) after the reported transaction, indicating he maintains a significant ownership stake in the company.

Want the newest filings?

This analysis covers the filing from 2026-04-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-21

The reporting person, Elizabeth E. Reed, who is the Chief Legal Officer and General Counsel of Travere Therapeutics, Inc., exercised 10,000 employee stock options and immediately sold the same number of shares at a weighted average price of $27.3420 per share.
The stock option exercise and sale were made pursuant to a pre-existing written plan that meets the requirements of Rule 10b5-1(c) of the Securities Exchange Act, indicating a planned transaction rather than an opportunistic trade.
Following the transaction, the reporting person still holds 90,270 shares of Travere Therapeutics' common stock, indicating a continued ownership interest in the company.

Other reports for Travere Therapeutics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.